Omeros Corporation (OMER) surged 148.54% to $10.19, up $6.09, after announcing a $2.1 billion licensing and asset purchase deal with Novo Nordisk for its MASP-3 inhibitor drug zaltenibart - OMS906.
The agreement grants Novo Nordisk exclusive global rights to develop and commercialize the candidate for rare blood and kidney disorders, with upfront and near-term payments of $340 million and additional milestone-based payouts.
The stock opened at $11.53, hit a high of $12.77, and a low of $4.33, compared with a previous close of $4.10. It trades on the NasdaqGS, with volume soaring to 77.9 million shares versus an average of 1.2 million. OMER has ranged between $0.92 and $12.87 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.